---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-006629"
form_type: "8-K"
ticker: "PLSE"
cik: "0001625101"
company_name: "PULSE BIOSCIENCES, INC."
filed_at: "2026-03-03T23:59:59+00:00"
generated_at: "2026-05-15T22:17:19.878255+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "medium"
source: SEC EDGAR
---

# Pulse Biosciences updates investor deck with nPulse catheter development, cites 'unprecedented' EU feasibility data

## Summary
- Updated investor presentation posted on website includes summary financial info and product development update.
- Next-generation nPulse cardiac catheter under development is highlighted.
- Company strengthening focus on EP cardio ablation following 'unprecedented' EU feasibility study outcomes.
- Presentation to be used in meetings with investors and analysts.

## SEC filing metadata
- accession: 0001437749-26-006629
- form_type: 8-K
- ticker: PLSE
- cik: 0001625101
- company_name: PULSE BIOSCIENCES, INC.
- filed_at: 2026-03-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1625101/000143774926006629/0001437749-26-006629-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1625101/000143774926006629/plse20260302_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-006629
- JSON: https://secwatch.observer/filing/0001437749-26-006629.json
- Plain text: https://secwatch.observer/filing/0001437749-26-006629.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.